2 results
Approved WMOCompleted
Primary objective:To demonstrate the non-inferiority (NI) of the humoral immune response in healthy participants 50-59 YOA compared to OA (>=60 YOA) for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.To demonstrate…
Approved WMOCompleted
Primary:Compare the efficacy of single IV injection with otilimab 90 mg in adults with severe pulmonary COVID-19 related disease.Secondary:Other aspects of efficacy. Safety and tolerability.